Reata Pharmaceuticals (RETA) is Initiated by Piper Jaffray to Overweight, Price Target at $33

Reata Pharmaceuticals (RETA) was Initiated by Piper Jaffray to “Overweight” and the brokerage firm has set the Price Target at $33. Piper Jaffray advised their investors in a research report released on Jun 20, 2016.

Reata Pharmaceuticals

Leave a Reply

Reata Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Reata Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.